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Abstract
Drugs with prolonged, on-target residence time often show superior efficacy, yet general strategies 
for optimizing drug-target residence time are lacking. Here, we demonstrate progress toward this 
elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversible 
covalent inhibitors. Utilizing an inverted orientation of the cysteine-reactive cyanoacrylamide 
electrophile, we identified potent and selective BTK inhibitors that demonstrate biochemical 
residence times spanning from minutes to 7 days. An inverted cyanoacrylamide with prolonged 
residence time in vivo remained bound to BTK more than 18 hours after clearance from the 
circulation. The inverted cyanoacrylamide strategy was further utilized to discover fibroblast 
growth factor receptor (FGFR) kinase inhibitors with residence times of several days, 
demonstrating generalizability of the approach. Targeting noncatalytic cysteines with inverted 
cyanoacrylamides may serve as a broadly applicable platform that facilitates “residence time by 
design”, the ability to modulate and improve the duration of target engagement in vivo.
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Drug discovery programs historically have sought to optimize molecules by maximizing the 
thermodynamic affinity (i.e., Kd or IC50) of the drug-target interaction. Less attention has 
been given to drug residence time (τ)1, which is defined as the inverse of the off-rate (koff) 
such that τ = 1/koff. Recently, it has become clear that drug-target residence time, rather than 
affinity, often drives pharmacodynamic activity and disease efficacy in vivo2-4. Hence, 
residence time should be a key focus during the drug discovery process5-7. A current lack of 
systematic approaches to design molecules with slow off-rates has hindered efforts to 
discover drugs with prolonged residence time.
Inhibitors that form a reversible covalent bond with a noncatalytic cysteine of their target 
may provide a widely applicable strategy for obtaining prolonged residence time. An 
approach to discover such inhibitors was recently reported8,9. In this work, a 
cyanoacrylamide electrophile attached to a kinase-recognition scaffold was designed to form 
a covalent but fully reversible bond with Cys436 in the C-terminal kinase domain of RSK2. 
These cyanoacrylamide inhibitors provided sustained engagement of RSK2, with 
biochemical residence times up to 6 hours9. Despite these promising results, it remained 
unclear how residence time could be systematically modulated. Moreover, characterization 
of cyanoacrylamide-based kinase inhibitors has to date focused on biochemical and cellular 
systems, and whether such inhibitors demonstrate prolonged residence time in vivo after oral 
administration has not been established.
Reversible covalent drugs have at least two theoretical advantages over their irreversible 
counterparts. First, relative to reversible covalent drugs, drugs that rely on intrinsically 
irreversible chemistry (e.g., acrylamides) are more likely to form permanent covalent 
adducts10-12 with off-target proteins, including closely related targets (e.g., off-target kinases 
with a homologous cysteine) as well as unrelated targets with hyper-reactive cysteines13. 
Second, and equally important, reversible cysteine engagement may enable fine tuning of 
inhibitor residence time, a feature that would facilitate utilization not only in therapeutic 
applications requiring sustained target engagement, but also in applications where more 
rapid target disengagement is preferred2. Since many drug targets, including kinases14-16, 
have an accessible cysteine in their binding site, there is broad opportunity to discover 
reversible covalent inhibitors for use across many therapeutic areas.
Bruton's tyrosine kinase (BTK) contains a noncatalytic cysteine (Cys481) that has been 
targeted by several inhibitors17-23. Among these compounds, ibrutinib17 is particularly 
noteworthy and was recently approved for treatment of the B cell malignancies chronic 
lymphocytic leukemia24 and mantle cell lymphoma25. Selective BTK inhibitors have also 
shown activity in collagen-induced arthritis and other rodent models of 
inflammation17,19,26,27, providing a rationale for BTK inhibition in autoimmune diseases. 
Given that irreversible acrylamide-based kinase inhibitors, including ibrutinib, have been 
shown to form permanent covalent adducts with kinase and non-kinase off-target proteins28, 
it is not clear whether such compounds have the requisite selectivity profile for use in 
autoimmune diseases, which typically require chronic dosing and a high safety margin.
Here, we explored the possibility of engaging BTK Cys481 with reversible covalent 
inhibitors. Inverting the orientation of the cyanoacrylamide relative to the kinase active site 
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and perturbing the steric and electronic environment of the electrophilic carbon led to the 
discovery of inhibitors with remarkably slow off-rates. These inhibitors exhibit biochemical 
residence times up to 7 days and illustrate the feasibility of fine-tuning inhibitor-BTK 
residence times across a wide dynamic range. An inhibitor that was orally bioavailable also 
demonstrated sustained BTK occupancy in vivo. The prolonged residence time and excellent 
kinase selectivity profile suggest potential applications of these inhibitors in chronic 
inflammatory diseases. The inverted cyanoacrylamide approach was further applied to an 
entirely different kinase and cysteine position (FGFR1 Cys486) and also resulted in 
inhibitors with prolonged and tunable residence time, illustrating broad applicability of the 
strategy to numerous drug targets.
Results
Design of reversible covalent BTK inhibitors
Structure-based design was used to identify lead molecules starting with scaffolds for which 
BTK crystallographic binding modes had been reported (Supplementary Results, 
Supplementary Fig. 1)29,30. A key challenge was identifying an accessible vector to Cys481 
that could accommodate a reversible cyanoacrylamide-based electrophile. A previous design 
strategy8,9 – linking the electrophilic β-carbon directly to a kinase-recognition scaffold – 
appeared suboptimal, as Cys481 is located outside the ATP binding site. To solve this 
problem, the cyanoacrylamide was inverted relative to the scaffold, orienting the 
electrophilic β-carbon toward the protein surface, distal to the active site. This novel 
orientation provided unexpected opportunities for modulating residence time. First, it 
allowed exploration of multiple vectors to a common pyrazolopyrimidine scaffold by 
coupling geometrically diverse, amine-containing linkers to the cyanoacrylamide carboxyl 
group. Second, it opened a previously unavailable path for manipulating the steric and 
electronic environment of the electrophilic β-carbon through the use of branched-alkyl 
capping groups (Fig. 1a).
To test whether alkyl capping groups with increased branching and steric size confer 
prolonged residence time, cyanoacrylamides 1-3 bearing a piperidine linker and a 
pyrazolopyrimidine scaffold were prepared (Fig. 1a). Cyanoacrylamides with branched-
alkyl capping groups are unique since the vast majority of cyanoacrylamides contain 
aromatic or heteroaromatic β-substituents (including previously reported reversible covalent 
kinase inhibitors8,9). Despite having similar potency in a cellular BTK occupancy assay 
under continuous exposure (Supplementary Fig. 2), compounds 1-3 exhibited distinct BTK 
residence times. This was assessed after extensively washing compound-treated Ramos B 
cells prior to labeling with an irreversible, pyrazolopyrimidine fluorescent probe (referred to 
here as PP-BODIPY) previously shown to penetrate cells and covalently bind BTK with 
high selectivity17. The tert-butyl-capped variant 3 had the longest residence time, showing 
55% BTK occupancy 20 hrs post-washout (Fig. 1b). The other inhibitors showed 
significantly reduced (2) or negligible (1) BTK occupancy after 20 hrs, demonstrating 
durability can be modulated by alterations to the capping group.
To provide molecular insight into the prolonged occupancy of 3, its co-crystal structure 
bound to the BTK kinase domain was solved at 2.2 Å resolution. The electron density 
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enabled unambiguous ligand placement (Supplementary Fig. 3), revealing strong density for 
the covalent bond and formation of two sp3-hybridized carbons resulting from Cys481 
addition to Cβ and protonation of Cα (Fig. 1c). Examination of the torsion angles and 
interactions surrounding this region revealed structural features that likely contribute to the 
prolonged residence time. To minimize 1,3-torsional strain and steric clashes with the 
protein, both the tert-butyl capping group and the piperidine amide are oriented in a manner 
that shields the critical proton attached to Cα, which must be removed prior to (or during) 
elimination of the Cys481 thiol (Fig. 1c). Moreover, this conformation prevents overlap 
between the Cα-H bond and the carbonyl π-system and therefore should reduce its kinetic 
and thermodynamic acidity31 and hence the rate of Cys481 elimination. Interactions 
between the tert-butyl capping group and a hydrophobic patch near Cys481, as well as a 
hydrogen bond between the amide carbonyl of 3 and the backbone NH of Cys481, may 
further stabilize the covalent complex. Consistent with the concept that these and other 
noncovalent interactions with the folded kinase domain play an essential role in kinetically 
trapping the complex, guanidine-mediated unfolding resulted in rapid regeneration of 3 in 88 
± 10% yield (Supplementary Fig. 4). Finally, the structure revealed that one of the tert-butyl 
methyl groups is solvent exposed, providing a site for attaching polar substituents that could 
potentially improve aqueous solubility.
BTK residence time modulated over a wide dynamic range
Although 3 exhibits sustained BTK occupancy in both cellular and biochemical assays 
(Supplementary Fig. 5a) and is highly selective over other kinases with a structurally 
homologous cysteine (>1,000-fold selectivity over EGFR and JAK3; 60-fold over ITK, 
Supplementary Fig. 5b), its low solubility and poor oral bioavailability prompted exploration 
of structural modifications throughout the molecule, with a primary focus on the linker and 
capping group. These efforts, which included substitutions on the scaffold (e.g., mono-
fluorination) and installation of a more flexible linker, led to the identification of 4 as a 
starting point for modulating BTK residence time (Fig. 2a). To bracket both extremes of the 
residence time spectrum, an acrylamide variant of 4 expected to bind irreversibly (5, referred 
to hereafter as PP-ir) and a non-electrophilic variant expected to have a rapid off-rate (6, 
referred to hereafter as PP-ne) were also synthesized (Fig. 2a).
To facilitate detection of subtle differences in inhibitor residence times, a kinetic 
competition assay was developed using recombinant, full-length BTK (Supplementary Fig. 
6). The assay measures the time an inhibitor prevents binding of a high-affinity fluorescent 
tracer added in large excess32-34. Inhibitor potency was also determined using a 
conventional enzymatic activity assay. Inhibitor 4 exhibited high potency (IC50 = 1.4 ± 0.2 
nM, Supplementary Fig. 7) and gradually dissociated from BTK over many hours at room 
temperature (τ = 22 ± 3 hrs) (Fig. 2b), suggesting that it forms a covalent but reversible 
bond with Cys481. In contrast, the acrylamide-containing inhibitor PP-ir showed no evident 
dissociation, suggesting irreversible cysteine engagement. The compound lacking an 
electrophile, PP-ne, was less potent (IC50 = 170 ± 50 nM) and dissociated within 5 minutes 
(Fig. 2c). Dasatinib, a potent noncovalent BTK inhibitor35 (IC50 = 0.5 ± 0.1 nM), had a 
residence time of only 0.46 ± 0.06 hrs, indicating that high potency does not necessarily 
predict slow dissociation.
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A comparison of both enantiomers of the methylpyrrolidine linker (4 vs. 7) revealed that the 
S-configuration provided greater durability (Fig. 2b). Maintaining the S-methylpyrrolidine 
linker, the capping group was revisited. This led to the discovery that inhibitors containing 
polar, branched-alkyl capping substituents, exemplified by morpholine 8 and oxetane 9 (Fig. 
2a), exhibited further increases in residence time. With a residence time of 167 ± 21 hours 
(one week) (Fig. 2b), 9 is to our knowledge among the most durable reversible inhibitors yet 
identified2,3. Trypsinization of the complex formed between BTK and 9 led to quantitative 
recovery of unaltered 9, confirming complete reversibility (Supplementary Fig. 8).
Examination of 21 cyanoacrylamide-containing pyrazolopyrimidines encompassing 4 and 
7-26 (Supplementary Table 1) revealed a graded continuum of BTK occupancy 24 hrs after 
adding the competitive tracer (Fig. 2d); discrete differences in BTK occupancy were also 
evident at earlier time points (Supplementary Table 1). Thus, residence time was tuned 
across a wide dynamic range via subtle structural perturbations to the linker and branched-
alkyl capping group. Little correlation was observed between durability and IC50 values in 
the BTK enzyme assay, consistent with the general inability of IC50 measurements to 
capture the true binding affinity of slow off-rate compounds (Fig. 2c). It is unlikely that 
inhibitors like 9 would have been discovered using a strategy focused solely on optimizing 
IC50 values, rather than residence time.
Several approaches were employed to corroborate the prolonged residence time observed 
with 9. First, the rate at which BTK enzymatic activity recovered after incubation with 
compound followed by dialysis was measured. Compound 9 demonstrated durable BTK 
inhibition, showing only 25% recovery of activity after 3 days of dialysis at room 
temperature (Supplementary Fig. 9). Compound 4 was also durable but to a lesser extent, 
reflecting the same rank order as the off-rate assay. In separate experiments, 9 demonstrated 
time-dependent inhibition of BTK enzymatic activity (Supplementary Figs. 10-11), as 
expected for an inhibitor with an extremely slow off-rate. kinact/Ki values were determined 
for compounds 4-9, and similar to the IC50 values, kinact/Ki did not correlate with residence 
time (Supplementary Fig. 11).
Durability of reversible covalent BTK inhibitors in cells
Cellular potency and durability were assessed using the ability of inhibitors to block binding 
of probe PP-BODIPY to BTK. Pre-incubation of Ramos B cells with 4, 7, 9, and PP-ir 
blocked BTK labeling in a dose-dependent manner (Fig. 3a; Supplementary Figs. 12-13). To 
test for durable BTK occupancy, cells were incubated with 9, extensively washed to remove 
unbound inhibitor, and subsequently incubated with PP-BODIPY 4 hrs after removal of 9. 
Inhibition of PP-BODIPY labeling by 9 was equally effective with and without washout 
(Fig. 3a), indicating durable interaction. The ability of 4-9 to block PP-BODIPY in Ramos 
cells was next compared 4 and 18 hrs post-washout, and a correlation was observed between 
biochemical residence time and durable occupancy in cells (Fig. 3b; Supplementary Fig. 14). 
A higher-throughput method for determining cellular BTK occupancy was developed based 
on an irreversible, biotin-labeled probe (27, referred to as PP-biotin, see Supplementary Fig. 
15a) and AlphaScreen technology36 (Supplementary Fig. 15b). Inhibitors 4, 7, 8, 9, and PP-
ir blocked PP-biotin binding to BTK with IC50 values from 5 ± 1 nM to 27 ± 11 nM 
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(Supplementary Fig. 15c). Similar to biochemical residence time measurements, a washout 
experiment in Ramos cells using Alphascreen detection indicated that reversible covalent 
BTK inhibitors exhibit varying degrees of durability, with 9 being the most durable (59% ± 
17% occupancy 18 hrs post-washout, Fig. 3c). Co-treatment with the protein synthesis 
inhibitor cycloheximide indicated that much of the apparent recovery of unoccupied BTK 
during the 18 hr washout period is due to BTK turnover and re-synthesis in Ramos B cells 
rather than compound dissociation (Supplementary Fig. 16).
BTK occupancy led to diminished signaling downstream of the B cell receptor, as revealed 
by a flow cytometry-based CD69 expression assay. In human whole blood, BTK inhibitors 
including 9 blocked CD69 expression following stimulation of the B cell receptor with anti-
IgM (Supplementary Figs. 17-18). Potent BTK inhibition in cells also required Cys481 as a 
C481S BTK mutant transfected into HEK293 cells was >50-fold less sensitive to 9 than 
wild-type BTK (Supplementary Fig. 19).
BTK inhibitor selectivity and in vivo residence time
To determine kinase selectivity, 9 was evaluated at concentrations of 1 μM and 0.1 μM in a 
254-kinase panel with subsequent enzyme IC50 determinations (Fig. 4; Supplementary Fig. 
20). Because BTK Cys481 is conserved in only 10 other kinases (BLK, BMX, EGFR, ERB-
B2, ERB-B4, ITK, MKK7, JAK3, TEC, and TXK), we hypothesized that 9 would inhibit a 
subset of these kinases without affecting kinases that lack this cysteine. Indeed, only 6 of 
254 kinases were inhibited by >90% at 1 μM of 9 (Fig. 4a; Supplementary Table 2); the 
sensitive kinases (BTK, BLK, BMX, ERB-B4, TEC, TXK) share the conserved cysteine as 
well as a threonine in the gatekeeper position. Furthermore, only BTK and BMX were 
inhibited by >90% at 0.1 μM of 9 (Fig. 4a; Supplementary Table 3). Importantly, other 
kinases that have this cysteine and are known to play critical tissue-specific homeostatic 
roles in vivo (EGFR, ERB-B2, ITK, JAK3) were unaffected by 9 (IC50 >3 μM, Fig. 4b). 
Compound 9 failed to inhibit signaling downstream of EGFR and the T cell receptor (Fig. 
4c), indicating selectivity in cells for the B cell receptor pathway.
We asked whether the sustained residence time of 9 in biochemical and cellular experiments 
translated into a prolonged pharmacodynamic effect in rodents. PP-BODIPY was used to 
determine the level of BTK target engagement in rat peripheral blood mononuclear cells 
(PBMC) at multiple times following an oral 40 mg/kg dose of 9. Levels of 9 in plasma were 
simultaneously determined to assess whether BTK occupancy was driven by prolonged 
residence time or high levels of 9 in circulation. The plasma level of 9 peaked at 104 ± 66 
ng/ml 1 hr after dosing and fell to 24 ± 17 ng/ml at 6 hrs and 3 ± 3 ng/ml at 14 hrs (Fig. 5). 
Since the IC50 of 9 in human whole blood is 146 ± 10 ng/ml (corresponding to 240 ± 20 nM, 
Supplementary Fig. 18), it seemed unlikely that the low plasma levels observed after 6 hrs 
could drive BTK target engagement. Assessment of BTK occupancy revealed that 74 ± 9%, 
82 ± 5%, 57 ± 9%, and 41 ± 15% of BODIPY probe labeling was blocked at 1 hr, 6 hrs, 14 
hrs, and 24 hrs after dosing, respectively (Fig. 5). Hence, despite being cleared from the 
circulation, 9 exhibits significant target engagement 24 hrs after oral dosing, reflecting its 
slow dissociation from BTK in vivo.
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Prolonged, tunable residence time of FGFR inhibitors
We sought to show that the strategy of tuning inhibitor residence time by varying 
cyanoacrylamide capping groups is generalizable beyond BTK. Cys486 of FGFR1, located 
in the kinase P loop, has previously been targeted with acrylamide-based irreversible 
inhibitors utilizing a pyrimidopyridine scaffold37. This cysteine is found in an active site 
region distinct from both Cys481 of BTK and Cys436 of RSK2 (Fig. 6a), providing an 
opportunity to demonstrate cyanoacrylamide-based cysteine targeting in a third distinct 
protein environment. A series of FGFR inhibitors were synthesized that all contain the same 
pyridopyrimidinone core and phenyl linker but a variety of electrophile capping groups. 
Inhibitors were all potent toward FGFR1 in an enzyme activity assay (IC50 ≤ 6 nM; 
Supplementary Table 4) but varied dramatically in their residence times, as exemplified by 
28, 29, and 30 (Fig. 6b and 6c). Compound 28, a highly durable inhibitor containing a 
spirocyclic capping group, maintained FGFR1 occupancy throughout the 24 hour assay 
period (τ > 150 hrs) whereas the equally potent but noncovalent FGFR inhibitor BGJ39838 
dissociated much more rapidly (τ = 1.9 ± 0.4 hrs; IC50 = 0.9 ± 0.1 nM) (Fig. 6c). Likewise, 
although both 28 and BGJ398 potently blocked FGF-stimulated ERK phosphorylation in 
human umbilical vein endothelial cells, only 28 maintained inhibition following extensive 
cell washout, indicating prolonged residence time in cells (Supplementary Fig. 21). The 
FGFR inhibitor series, encompassing compounds 28 through 38 (Supplementary Table 4), 
demonstrated a wide continuum of FGFR occupancy levels at 24 hours in the kinetic 
competition assay (Fig. 6d; Supplementary Table 4), indicating that simple modifications in 
the capping group and linker discretely modulated FGFR1 residence time over several 
orders of magnitude, analogous to the cyanoacrylamide pyrazolopyrimidine series toward 
BTK (Fig. 2c). Excellent kinase selectivity for the FGFR family was also obtained 
(Supplementary Fig. 22; Supplementary Tables 5 and 6). Many of the capping groups that 
provided prolonged residence time toward FGFR were distinct from those that provided 
prolonged residence time toward BTK, indicating that the unique protein environment of 
each cysteine residue determines which capping groups provide the greatest durability 
(Supplementary Figs. 23 and 24).
Discussion
By exploiting the intrinsic reversibility and facile tunability of inverted cyanoacrylamide-
based inhibitors, we demonstrated that BTK inhibitor residence time can be modulated in a 
discrete, stepwise manner. The strategy focused specifically on maximizing BTK residence 
time rather than binding affinity, and the biochemical and cellular assays reported in this 
work are applicable to other therapeutic targets for which optimization of residence time is 
crucial. Fine-tuning of the cyanoacrylamide capping group and linker attached to a kinase-
recognition scaffold culminated in the discovery of 9 (Fig. 2a), a reversible BTK inhibitor 
that binds to the intact kinase with a residence time of 7 days, while dissociating rapidly and 
quantitatively upon BTK proteolysis. Cyanoacrylamide 9 has good aqueous solubility (126 
μM at pH 7), is orally bioavailable, and provides sustained BTK engagement in vivo, lasting 
18 hours after clearance from the circulation. The apparent increased dissociation rate in 
cells relative to the biochemical assay likely reflects the increased temperature (37 °C vs. 23 
°C) and a more dynamic intracellular environment, including BTK turnover, re-synthesis, 
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and interaction with cellular binding partners. Despite these differences, results from the 
biochemical assay correlated with durability in cells (See Fig. 2b & Fig. 3).
A breakthrough came with the discovery that certain branched-alkyl capping groups with 
polar functionality can be attached to the cyanoacrylamide β-carbon to modulate BTK 
residence time. Such cyanoacrylamides have little precedent in the chemical literature, and 
prior to this work, it was unclear whether they would even be stable under physiological 
conditions. When certain capping groups and linkers are combined, noncovalent interactions 
with the protein (exemplified by the BTK/3 crystal structure), as well as conformational 
restriction proximal to the new covalent bond, increase the kinetic barrier to cysteine 
elimination and thereby stabilize the complex. Such capped cyanoacrylamides could 
potentially be used to modulate inhibitor residence time for many other cysteine-containing 
targets, and we demonstrated here generalizability beyond BTK by showing that Cys486 of 
FGFR1 could also be targeted with inverted cyanoacrylamide-based inhibitors (Fig. 6). No 
estimate of the total number of drug targets that contain an accessible cysteine (the 
“druggable cysteinome”) has yet been reported. However, among kinases, it has been 
estimated that 39% (200 of 518) contain an approachable cysteine in the ATP-binding 
pocket15, suggesting that the overall percentage of drug targets amenable to cysteine-
targeting is significant.
While targeting cysteines with inverted cyanoacrylamides likely has broad application, there 
are certain limitations to this approach. First, cyanoacrylamides with branched-alkyl capping 
groups have a high steric demand, potentially limiting their application to relatively 
unhindered and solvent-exposed cysteines. Second, although structure-based design is useful 
for identifying initial scaffolds and linkers that orient the cyanoacrylamide near the targeted 
cysteine, predicting which linker/capping group combinations will provide the desired 
residence time is not currently feasible. Nevertheless, because the optimization path involves 
late-stage installation of both the linker and the capping group onto a pre-assembled 
scaffold, fine-tuning inhibitor residence time is highly efficient. Through different 
combinations of linkers and capping groups, a wide range of residence times were covered 
by synthesizing 21 closely related compounds, all of which inhibit BTK enzyme activity in 
the low nanomolar range (Fig. 2d; Supplementary Table 1).
This study revealed that cysteine-targeted, reversible covalent inhibitors can exhibit 
residence times from minutes to days. For targets where prolonged residence time is desired, 
reversible covalent inhibitors may be able to mimic the long-lasting activity of irreversible 
inhibitors, with dissociation rates in vivo that approach the rate of target degradation and re-
synthesis. However, molecules with a fast off-rate are ideal for certain therapeutic targets, 
due to mechanism-based toxicity associated with permanent on-target inhibition. Well-
characterized examples include the cyclooxygenase inhibitor ibuprofen39,40, the NMDA 
receptor antagonist memantine41, and the D2 dopamine receptor antagonist clozapine42,43. 
For these targets, irreversible inhibition is not a clinically viable approach, but reversible 
covalent inhibition would still be appropriate. The ability to generate a series of ligands with 
residence times that span a wide temporal range, as demonstrated in this study, suggests it 
may be possible to match a ligand's residence time to the biological requirements of a drug 
target.
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BTK has been clinically validated as a target for B cell malignancies based on pioneering 
studies with the acrylamide-based inhibitor ibrutinib24,25. In addition to inhibiting BTK and 
related Tec-family kinases, ibrutinib targets more distantly related kinases, including EGFR, 
MKK7, ITK, and JAK3, which have a cysteine equivalent to BTK Cys48117,28,44. 
Moreover, when added to cells at therapeutically relevant concentrations, acrylamide-based 
probes nearly identical to ibrutinib and a clinical EGFR inhibitor were shown to form 
irreversible adducts with dozens of other cysteine-containing proteins28. Irreversible adducts 
have historically been a concern within drug discovery due to the relationship between 
covalent drug binding and the potential for idiosyncratic drug toxicity10,12,45,46. Irreversible 
modification of off-target cysteines may be especially problematic in tissues exposed to high 
initial drug concentrations after oral administration (often in the micromolar range), such as 
the gastrointestinal tract and liver. By eliminating the possibility of irreversible binding to 
off-target proteins, a reversible covalent molecule may provide reduced risk of idiosyncratic 
drug reactions and therefore may be safer than an analogous irreversible inhibitor. Given the 
intrinsically reversible nature of the cyanoacrylamide/cysteine interaction, the probability of 
forming permanent adducts using a reversible covalent BTK inhibitor such as 9 is 
negligible. Moreover, 9 has outstanding kinome-wide selectivity (Fig. 4), avoiding all 
kinases that lack the conserved cysteine and many physiologically important kinases that 
have this cysteine, including EGFR, ERB-B2, ITK, JAK3, and MKK7.
In addition to their established roles in the treatment of B cell cancers, BTK inhibitors may 
have beneficial effects in autoimmune diseases. Diseases such as rheumatoid arthritis and 
lupus erythematosus, which are ameliorated by BTK inhibitors in animal models17,19,26,27, 
typically require chronic dosing and a high safety margin, favoring drugs that are highly 
selective with minimal off-target effects. Reversible covalent BTK inhibitors such as 9 
appear well suited for potential use in autoimmune disorders and are currently being 
advanced for clinical studies. More broadly, inverted cyanoacrylamides with branched-alkyl 
capping groups represent a new platform for targeting noncatalytic cysteines. Wide 
application of this approach has the potential to improve small-molecule residence times 
across diverse targets and disease areas.
Online Methods
Chemical synthesis
The synthesis of compounds is described in the Supplementary Note.
BTK kinase domain cloning, expression and purification—Human BTK kinase 
domain (residues 382-659) was inserted into pFastBac-1 by InFusion cloning following the 
manufacturers protocol (Clontech). During PCR amplification a TEV-cleavable 6x-His tag 
was introduced on the BTK N-terminus. This plasmid was then used to transform DH10α 
MultiBac cells for preparation of the expression bacmid. Sf21 cells were transfected with the 
MultiBac bacmid using Fugene HD transfection reagent according to the manufacturer's 
instructions (Roche), and virus was propagated following published methods. The BTK 
kinase domain was subsequently expressed in Sf21 cells by infection of 2.0 L of cultured 
cells with 20 mL virus solution such that cell growth was halted immediately. The cells were 
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collected by centrifugation (800 g × 15 min) and the pellets resuspended in 50 mL lysis 
buffer (50 mM Hepes, pH 7.5, 400 mM NaCl, 1.5 mM DTT) supplemented with 1 × 
protease inhibitor cocktail (Roche). The cells were lysed by 5 passes through a cell 
homogenizer. The cellular debris was pelleted by centrifugation (30k g × 30 min). The 
protein was bound in batch to Ni-NTA agarose beads in binding buffer (lysis buffer + 20 
mM imidazole) for 4 h at 4 °C. The beads were washed with additional binding buffer (4 × 5 
mL) and the protein was eluted with 3 × 0.5 mL portions of elution buffer (lysis buffer + 
300 mM imidazole). The His tag was cleaved by addition of AcTev protease with 
concomitant dialysis overnight into cleavage buffer (50 mM Tris, pH 8.0, 0.5 mM EDTA, 1 
mM DTT). The resulting soluble protein was purified further by gel filtration on an S75 
column (gel filtration buffer: 20 mM Tris, pH 8.0, 50 mM NaCl, 3 mM DTT). The protein 
was then concentrated to 16.8 mg/mL, flash frozen in LN2 and stored at -80 °C. The final 
yield was 4 mg of protein.
Crystallization, data collection and structure solution—BTK kinase domain (6.0 
mg/ml, 0.18 mM) was treated with compound 3 (1 mM) in 10% DMSO and the mixture was 
incubated on ice for 30 min, followed by ultracentrifugation in a TLA100 rotor for 30 min at 
90,000 rpm at 4 °C. Crystals of BTK-KD/3 were grown by mixing 1 μL of protein with 1 μL 
of precipitant solution composed of 0.1 M MES pH 6.5, 0.2 M (NH4)SO4, and 30% (w/v) 
PEG 5000 MME, at 4 °C. The crystals grew as stacked plates that were crushed and 
individual crystals were cryoprotected in mother liquor supplemented with 15% ethylene 
glycol and frozen in a stream of liquid nitrogen at 100 K. The crystals belonged to the space 
group P21 with unit cell parameters a=43.5 Å; b=76.1 Å; c= 88.2 Å; α=90.0°; β=96.5°; 
γ=90.0° and contained two copies of the complex. All datasets were collected on a stream of 
liquid nitrogen at 100K at 1.000 Å wavelength on the 8.2.1 beamline of the Advanced Light 
Source at the Berkeley National Laboratory. Diffraction data were integrated and scaled 
with the program XDS47. The structure of the BTK-KD/3 complex was solved by molecular 
replacement using data to 2.2 Å and structure 3GEN as search model in program Phaser48, 
followed by several rounds of manual rebuilding and restrained refinement with programs 
Coot49 and Phenix50. The structure refinement converged to R and Rfree values of 17.4% 
and 20.8%, respectively with 96% favored and 0.2% Ramachanran outliers as validated with 
the Molprobity server51. See Supplementary Fig. 3 for data collection and refinement 
statistics.
Dissociation of compound 3 from BTK after guanidine-mediated unfolding
BTK (1.5 μM in 20 mM Tris, 50 mM NaCl, pH 8.0) or buffer alone was incubated with 1 
μM compound 3 (1% DMSO v/v final, 10 μL total volume) for 30 min at room temperature. 
Guanidinium hydrochloride (6 M, 10 μL) was added to each solution and the mixtures were 
incubated for 30 min at 37 °C. Acetonitrile (40 μL) was added to each solution, followed by 
water with 0.1% formic acid (10 μL). The resulting solutions were analyzed by LC-MS/MS, 
and 3 was quantified using a MRM method and calibration curve (Waters Acquity UPLC/
ESI-TQD instrument with a 2.1 × 50 mm Acquity UPLC BEH C18 column). Percent 
recovery of the BTK-containing sample was determined relative to the control sample 
lacking BTK.
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Competition labeling assay in Ramos cells with PP-BODIPY—Ramos cells were 
grown in RPMI 1640 media supplemented with 10% FBS and pen/strep antibiotics under 
5% CO2. Cells (1 mL, 1 – 1.5 × 106) in growth media were treated with drug (0.1% DMSO) 
for 1 h at 37 °C. PP-BODIPY was added to a final concentration of 1 μM and the cells were 
incubated for an additional hour at 37 °C. The cells were collected by centrifugation (650 g 
× 3 min) and washed with PBS. The cells were flash frozen in LN2 and stored at -80 °C. 
The cell pellets were resuspended in 50 μL CelLytic M (Sigma, #C2978) supplemented with 
1 × Roche complete protease inhibitors and incubated 15 min at 4 °C. The cellular debris 
was removed by centrifugation (20k g × 10 min) and the supernatents were normalized for 
total protein concentration and subjected to SDS-PAGE analysis. The resulting gel was 
scanned for fluorescence and either probed by western blot for total BTK (α-BTK antibody 
– Cell Signaling #C82B8 or BD Biosciences Cat#611117, 1:500) and α-tubulin (anti-α-
tubulin antibody – Sigma #T6199) or stained with Coomassie Brilliant Blue for total protein.
Cellular durability studies using the PP-BODIPY occupancy probe—Ramos B 
cells were seeded at a concentration 1 × 106 cells/well in a 12-well plate. Compounds were 
added to a final inhibitor concentration of 1 μM and the plates were incubated at 37 °C for 1 
hr. Cells were washed 3 times to remove unbound inhibitor and returned to culture for the 
indicated time. Following the washout period, cells were incubated with 1 μM PP-BODIPY 
for 1 hr at 37 °C to evaluate inhibitor occupancy. Cells were pelleted, washed with PBS 
once, and 40 μL of lysis buffer (CelLytic M, Sigma #C2978) was added to each well. To 
evaluate the occupancy of BTK with PP-BODIPY and the total BTK present in each sample, 
gels were analyzed by fluorescent scanning and Western blot as described above. When the 
dependence of BTK occupancy on new protein synthesis was evaluated, 100 μL of 
cycloheximide (50 μg/ml) or culture media alone (10% FBS/RPM1 1600) was added to 900 
μL of cells for 30 minutes at 37 °C to a final concentration of 5 μg/ml cycloheximide, 
followed by addition of BTK inhibitors.
Biochemical residence time using fluorescence competition—Using an assay 
buffer of 50 mM Hepes pH 7.5, 10 mM MgCl2, 0.01% Triton-X 100, and 1 mM EGTA, 1 
μL of 15 μM compound was added to 9 μL of 0.5 μM BTK (Invitrogen PV3587) in a 96 well 
polypropylene plate. Following 30 minutes of incubation, the mixture was diluted in assay 
buffer. A dilution of 25-fold was utilized for time course studies with 4-9, and a 5-fold 
dilution was used for occupancy determinations measured at solely 1, 6, and 24 hours; 
varying the dilution in this range was demonstrated to have negligible effect on 
determination of BTK occupancy. 10 μL of diluted mixture was transferred to a Greiner 384 
well black plate. Europium-coupled Anti-6XHis Ab (Perkin Elmer AD0205) and Tracer 178 
(Invitrogen PV5593) were added to a final concentration of 15 nM and 0.75 μM, 
respectively, in 20 μL volume. Data was acquired using a Perkin Elmer Envision plate 
reader (Model 2101) containing LANCE TR-FRET compatible excitation and emission 
filters. Fluorescence at 665 nM and 615 nM wavelengths were collected at various times. In 
each experiment, a condition that provides the maximum signal (max) was acquired 
consisting of the signal from enzyme, Europium-coupled Anti-6XHis Ab, and Tracer 178 in 
the absence of test compound. A background signal (bkg) was also acquired where a 1 μM 
concentration of PP-ir was added to completely block Tracer 178 binding. Data for each test 
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compound was reported as % BTK bound, which is calculated as 100*(1 -(cmpd - bkg)/
(max – bkg)). In order to determine the koff and residence time τ, data were fit using a 
decreasing exponential function of the form % occupancy = (100 - Plateau)*exp(-koff*time) 
+ Plateau using GraphPad Prism software. Residence time τ was determined using τ = 1/
koff. Biochemical residence time studies using FGFR1 (Invitrogen PV4105) were performed 
using a similar procedure except that a 60 minute enzyme/compound incubation time was 
utilized, the dilution following pre-incubation was 100-fold, and a Cy5-labeled 
pyridopyrimidinone was utilized as a tracer.
Enzymatic IC50 assays—Inhibitor potency in a BTK enzymatic assay was determined 
using the microfluidic-based LabChip 3000 Drug Discovery System from Caliper Life 
Sciences that uses capillary electrophoresis to separate phosphorylated and non-
phosphorylated peptides. Twelve concentrations of inhibitor were first pre-incubated with 
BTK for 15 minutes. Enzyme, inhibitor, peptide substrate, and cofactors (ATP and Mg2+) 
were then combined and incubated at 25 °C. The final buffer was 100 mM HEPES, pH 7.5, 
0.1% BSA, 0.01% Triton X-100, 1 mM DTT, 10 mM MgCl2, 10 μM Sodium 
Orthovanadate, 10 μM Beta-Glycerophosphate, 16 μM ATP, and 1% DMSO. At the end of 
the incubation, the reaction was quenched by an EDTA-containing buffer. Negative controls 
(containing no inhibitor) and positive controls (acquired in the presence of 20 mM EDTA) 
were simultaneously evaluated to calculate percent inhibition at each compound 
concentration. The IC50 values were determined by fitting the inhibition curves using a 4 
parameter sigmoidal dose-response model using XLfit 4 software (IBDS). To measure the 
effect of pre-incubation time on compound IC50, the protocol above was modified such that 
the pre-incubation time between compound and BTK enzyme was 0 minutes, 10 minutes, 30 
minutes, 90 minutes, and 180 minutes. The determination of enzymatic IC50 values for 
BLK, BMX, EGFR, ERB-B2, ERB-B4, ITK, JAK3, MKK7, TEC, and TXK was performed 
as described above except that the concentration of kinase, the peptide substrate, and the 
ATP concentration were optimized for each kinase. Enzymatic IC50 data was acquired by 
Nanosyn, Inc. (Santa Clara, CA; www.nanosyn.com).
BTK progress curve analysis
Progress curves of BTK peptide phosphorylation were acquired at six concentrations. The 
real-time curves were obtained for a total of 5 hrs using the climate controlled Caliper 
LabChip instrument. The obtained curves were fit using XLfit4 software to the time 
dependent inhibition equation: [P] = Vs*t + ((Vi-Vs)/Kobs)*(1-exp(-Kobs*t)). In the 
equation: Vi is the initial velocity, Vs is the steady state velocity, and Kobs reflects the rate 
of inactivation. For rapid equilibrium compounds, a linear fit was used: [P]=Vi*t. For time 
dependent inhibitors, the obtained Kobs values were plotted against compound 
concentration using either a hyperbolic or a linear fit. From these plots, kinact and Ki were 
determined. Progress curve data was acquired by Nanosyn, Inc. (Santa Clara, CA; 
www.nanosyn.com).
Kinase selectivity panel—Kinase selectivity determination using a 254-kinase panel was 
performed by Nanosyn, Inc. (Santa Clara, CA; www.nanosyn.com).
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Dissociation of compound 9 from BTK after trypsinization
A mixture of 2 μM BTK (Invitrogen PV3587) and either 9 (0.6 μM) or PP-ir (0.6 μM) was 
incubated at room temperature for 60 minutes in an assay buffer of 20 mM Hepes pH 7.5, 10 
mM MgCl2, 150 mM NaCl, 5% Glycerol, 0.05% Triton-X 100, and 1 mM 2-
mercaptoethanol. In parallel 9 (0.6 μM) and PP-ir (0.6 μM) were also incubated with the 
BTK enzyme storage buffer alone (50 mM Hepes pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 
0.05% Triton X-100, 4 mM 2-mercaptoethanol, 50% Glycerol). A trypsin stock solution 
(Sigma T1426) was prepared to 1 mg/ml in assay buffer. 60 μL of both the enzyme/
compound mixture and the storage buffer/compound mixture were added to 120 μL of 1 
mg/ml trypsin. Liquid chromatography-mass spectrometry of the samples was performed by 
the analytical chemistry group of the Molecular Medicine Research Institute 
(www.mmrx.org). In order to calculate inhibitor reversibility, the average mass spectrometry 
peak area of the compound/BTK/trypsin samples was divided by the peak area for the 
samples containing compound/storage buffer/trypsin to get the % Reversibility.
BTK cell occupancy using Alphascreen—To treat Ramos B cells with compounds, 
100 μL of 1 × 106 cells were cultured in a 96-well round bottom polypropylene plate. 10 μL 
of a 1:3 dilution series of compound prepared in media containing 1.1% DMSO was added 
in duplicate, and 10 μL of media with 1.1% DMSO alone was added to control wells. The 
plates were incubated at 37 °C for 1 hr. The PP-biotin probe was prepared at 15 μM from a 5 
mM stock using media, and 2.5 μL of 15 μM PP-biotin was added to all wells except DMSO 
control wells to a final concentration of 330 nM. In DMSO control wells, 2.5 μL of media 
containing 0.3% DMSO was added. The plates were incubated for 1 hr at 37 °C. Cells were 
pelleted, washed with PBS once, and 60 μL of lysis buffer (Cell Lytic M, Sigma #C2978) 
was added to each well. The plate was incubated for 15-20 minutes on ice and centrifuged 
for 5 minutes at 2000 rpm at 4 °C. The lysate was transferred to a new polypropylene plate 
and either stored at -80 °C or used immediately. According to the Alphascreen 
manufacturer's protocol (Alpha technology Protein A detection kit, Perkin Elmer catalog 
6760617C), 1X buffer, 200 μg/ml acceptor beads, 30 nM BTK antibody (BTK, BD 
Biosciences, Cat# 611117) and 200 μg/ml streptavidin donor beads were prepared. To each 
well, 5 μL of acceptor beads and BTK antibody were added. The plate was sealed and 
incubated at room temperature for 30 minutes. Then 10 μL of lysate was added, and the 
plate was incubated at room temperature for 30 minutes. 5 μL of streptavidin donor beads 
was added to each well in a dark room. The plate was sealed with a plate sealer and 
incubated at room temp on the shaker for 30 minutes. The plate was read using the Perkin 
Elmer Envision Model 2101 plate reader compatible with Alphascreen. % Occupancy was 
calculated from the control samples that were either untreated with test compound 
(maximum signal) or were not treated with PP-biotin (minimum signal). IC50 values were 
determined by fitting dose response curves to a 4 parameter sigmoidal function using 
GraphPad Prism software.
BTK cell durability using Alphascreen—To treat Ramos B cells with compounds, 1 
ml of 1 × 106 cells per well were cultured in a 12-well polystyrene plate. 100 μL of test 
compound was added to cells to a concentration of 1 μM, and 100 μL of media with 1.1% 
DMSO was added to control wells. The plates were incubated at 37 °C for 1 hr. Cells were 
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transferred to microfuge tubes, pelleted and washed three times using media, and transferred 
to a new 12-well plate. The plates were incubated for either 4 hr or 18 hr. The PP-biotin 
probe was prepared at 15 μM from a 5mM stock using media, and the probe was added to 
wells at a concentration of 330 nM. The plate was incubated for 1 hr at 37 °C. Cells were 
pelleted, washed with PBS once, and 60 μL of lysis buffer (Cell Lytic M, Sigma #C2978) 
was added to each well. Lysates were evaluated for BTK occupancy using Alphascreen as 
described above.
Human whole blood CD69 expression assay—Human whole blood collected at 
Stanford Blood Bank in sodium heparin was incubated for 1 hr at 37 °C/5% CO2 in a 
humidified incubator with a dilution series of compound or 0.5% DMSO alone as a control. 
Samples were then stimulated with 50 μg/ml of Goat F(ab')2 anti-human IgM (Southern 
Biotech Cat#2022-14) for 16-18 hrs in a 37 °C/5% CO2 humidified incubator. The blood 
was stained for CD69 antigen expression on human B cells with BD Biosciences antibodies 
CD20-FITC (Cat#555622), CD69-APC (Cat#5555633), and corresponding isotype controls 
according to manufacturer's recommendations. Red blood cells were lysed with 1X BD 
Biosciences Lysis buffer (Cat#555899) according to manufacturer's recommendations. Cells 
were washed and resuspended in 1% bovine serum albumin in PBS and analyzed via flow 
cytometry on a Cytex DxP11 instrument using FlowJo v7.6.4. The percent of CD69 positive 
cells was plotted as a function of inhibitor concentration and fit to a sigmoidal dose-response 
using GraphPad Prism software to evaluate inhibitor potency.
T cell receptor and EGFR pathway analysis—The T cell receptor/NFAT reporter 
assay and the EGFR receptor/AP-1 reporter assay were performed by Thermo Fisher 
Scientific as part of their SelectScreen® Pathway Profiling Service.
BTK and BTK[C481S] cell assay
The transient transfection assay comparing the activity of BTK wt and BTK(C481S) was 
performed by Cell Assay Innovations (Beverly, MA) using ClariCELL™ technology 
(www.cellassayinnov.com). HEK293 cells were transfected with a vector expressing 
sequence verified for full length human BTK or BTK[C481S], then dispensed into multi-
well plates. Test compounds were added, and cells were incubated for 2 hours. The cells 
were lysed, and an ELISA was performed by capturing the BTK or BTK[C481S] and 
detecting autophosphorylation levels using a generic anti-phosphotyrosine antibody. BTK 
and BTK[C481S] dependent kinase activity in these assays were validated by using a 
kinase-deficient BTK[K430R] control.
In vivo analysis—Sprague Dawley outbred female rats (Harlan Laboratories) were used 
in these studies. Study animals were dosed orally at 40 mg/kg with 9 formulated as a 
suspension in 0.5% methylcellulose. Treatment and vehicle groups consisted of 3 and 4 
animals per group, respectively. BTK occupancy was measured on individual animals in 
each group, and the data represented is the average of two independent studies. Blood was 
drawn via cardiac puncture, 4-5 ml, for PK/PD analysis. Blood plasma exposure from each 
animal was analyzed for the levels of test compound by LC/MS/MS analysis methods. 
Samples were injected on a Shimadzu LC20AD HLPC system connected to a Sciex 
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API4000 QTrap mass spectrometer. A Phenomenex Gemini column (2.1 × 50 mm) was used 
at 40 °C utilizing a flow rate of 400 μL/minute. Mobile Phase A was 0.1% formic acid in 
water and mobile phase B was 0.1% formic acid in acetonitrile. A linear gradient of 5 – 98% 
B over 2.5 minutes was used. The mass spectrometer was operated in positive ion 
electrospray mode with multiple reaction monitoring for maximum sensitivity. Sciex 
Analyst software (version 1.6) was used for LC/MS/MS instrument control and acquisition. 
Compound concentration was determined against a standard curve of internal standard 
versus compound peak area ratio. Rat PBMC were isolated with GE Ficoll-Paque Plus 
(Cat#17-1440-03) according to manufacturer's recommendations. Freshly isolated PBMC, at 
10-20 × 106 cells, were incubated with 1 μM PP-BODIPY for 1 hr. Protein lysates were 
separated on a 4-12% Bis-Tris SDS-Page gel. The BTK-associated fluorescence signal was 
detected by scanning the gel on a Typhoon image scanner (GE Healthcare). Total BTK was 
subsequently detected via Western blotting with a BTK antibody (D3H5 clone, Cell 
Signaling Cat#8547) and an AlexaFluor647 anti-rabbit IgG (H+L) secondary antibody 
(Invitrogen, Cat#A31573). The signal was quantified using ImageQuantTLv7.0 software. 
All animal procedures were performed in accordance with the Guide for the Care and Use of 
Laboratory Animals and had prior approval by Principia Biopharma's IACUC adhering to 
Protocol PRN-01-2011.
Alphascreen ERK phosphorylation
Human umbilical vein endothelial cells (HUVECs) were utilized to determine compound 
potency by measuring FGF-induced phospho-Erk1/2 phosphorylation. Approximately 
30,000 cells were seeded per well in a 96-well cell culture plate at 37 °C overnight. Cells 
were incubated in recommended HUVECs media with 10% fetal bovine serum. After 24 hrs 
of incubation, cells were grown in serum free media for 1 hr prior to compound treatment. 
Compound dilutions were added to cells and incubated for 1 hr at 37 °C, starting at a 
concentration of 1 μM, and decreasing in tripling dilutions to a final concentration of 0.05 
nM. After a 1 hour incubation period, cells were stimulated with 50 ng/ml of FGF2 for 10 
mins. The reaction was stopped by adding 100 μl of ice cold PBS and washed three times. 
After washing, cells were lysed with 50 μL of 1× Lysis Buffer (pERK SureFire kit, 
PerkinElmer). Lysates were incubated in a pERK SureFire reaction mixture for a total of 4 
hrs as recommended by the manufacturer's protocol. At the end of the incubation period, 
pERK activity was measure using an Envision multilabel reader (PerkinElmer). The raw 
signal for pERK activity was used to calculate an IC50 inhibition value as a function of log 
compound concentration for each compound using Prism software from GraphPad.
phosphoERK washout assay
HUVECs were prepared at a concentration of 0.5 × 106 cells/well in a 6 well plate seeded 
overnight. Cells were starved in RPMI for one hour prior to the addition of compound (at a 
concentration 10-fold greater than the compound IC50) or DMSO for 1 hour at 37 °C. Cells 
were then washed three times to remove unbound inhibitor and returned to culture for the 
indicated time. Following the washout period, cells were stimulated with 50 ng/ml basic 
FGF (R&D systems Cat#233-FB) for 10 minutes at 37 °C. Cells were pelleted, washed with 
cold PBS once, and 40 μl of lysis buffer (Cell Lytic M, Sigma #C2978) was added to each 
tube. The samples were incubated for 15-20 min on ice and centrifuged for 5 min at 2000 
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rpm at 4 °C. The lysate was transferred to a new Eppendorf tube and either stored at -80 °C 
or used immediately. Lysates were added to gel loading buffer and separated using gel 
electrophoresis. Gels were transferred onto a nitrocellulose membrane and probed for pERK 
(1:1000 dilution; Cell Signaling Cat#4370) and total ERK (1:2000 dilution; Cell Signaling 
Cat#9102).
Kd determination using β-mercaptoethanol
Solutions were prepared containing 0, 0.5, 1.5, 5, 15, 50, 150, and 500 mM β-
mercaptoethanol (BME) in a 1:1 mixture of ethanol and phosphate buffered saline (pH 7.4, 
PBS). Aliquots of a 10 mM DMSO stock solution of test compound (4 μL) were separately 
added to 196 μL aliquots of the above-described ethanol/PBS solutions containing 0 to 500 
mM BME. After these solutions had been allowed to stand at room temperature for one 
hour, they were analyzed using an Agilent 1200 LCMS system equipped with a 50 × 2 mm 
Phenomenex Luna 5μ C18 100A column. Samples were eluted using a gradient of 
acetonitrile and water, with both solvents containing 0.1% formic acid. Peaks corresponding 
to parent and BME adduct were identified by their masses and the percent parent in each 
sample was determined by measuring the area under the curve for these peaks in the 254 nm 
UV trace. Percent parent was plotted versus the log of the BME concentration using 
GraphPad Prism to determine a Kd for the reaction. For 9, parent and BME adduct were not 
well separated on the LCMS and percent parent was determined using the area under the 
curve of the appropriate extracted mass peaks from the positive ion trace.
Rate of β-mercaptoethanol reversibility
A 10 μL aliquot of a 10 mM DMSO solution of the test compound was added to a 90 μL 
aliquot of a 15 mM solution of BME in 1:1 PBS/ethanol. After the mixture had been allowed 
to equilibrate for about one hour at room temperature, it was analyzed using an Agilent 1200 
LCMS system equipped with a 50 × 2 mm Phenomenex Luna 5μ C18 100A column. The 
sample was eluted using a gradient of acetonitrile and water, with both solvents containing 
0.1% formic acid. Peaks corresponding to parent and BME adduct were identified by their 
masses and the percent adduct in the sample was determined by measuring the area under 
the curve for these peaks in the 254 nm UV trace. This value was used as the T=0 percent 
adduct. The sample was then diluted 10-fold by adding a 50 μL aliquot to a 450 μL aliquot 
of 1:1 PBS/ethanol. The diluted sample was then immediately injected on the LCMS using 
the same conditions used for the T=0 data point. LCMS injections were repeated as often as 
the LCMS method would allow (approximately every 6 minutes) for about one half hour. 
Percent adduct for each time point was determined as described above, then plotted and 
analyzed using GraphPad Prism. For 9, parent and BME adduct were not well separated on 
the LCMS and percent adduct was determined using the areas under the curve of the 
appropriate extracted mass peaks from the positive ion trace.
Structure coordinates—The coordinates of the BTK/3 crystal structure are deposited in 
the Protein Data Bank with accession code 4YHF.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Reversible covalent BTK inhibitors based on inverted cyanoacrylamides
(a) Cyanoacrylamides, attached via a piperidine linker to a pyrazolopyrimidine scaffold, are 
capped with alkyl groups of increasing steric demand (1-3). (b) Inhibitors 1-3 have distinct 
levels of BTK durability in cells following inhibitor washout. Ramos B cells were treated 
with DMSO or 1-3 (1 μM) for 1 hr, washed 3 times with PBS, and incubated in compound-
free media at 37 °C. After 4 or 20 hrs, cells were treated with 1 μM PP-BODIPY (the 
irreversible probe that labels BTK Cys481) for 1 hr and then lysed and analyzed by in-gel 
fluorescence. Occupancy was calculated from the normalized in-gel fluorescence intensity 
divided by the DMSO control value and subtracted from 100% (mean ± SD, n = 3). (c) Co-
crystal structure of 3 bound to BTK at 2.2 Å resolution. The covalent bond between Cys481 
and Cβ, newly formed CαH, and select hydrogen bonds are indicated. Two of the capping 
group methyls form hydrophobic contacts with Leu483 and Arg525, while the third is 
solvent exposed.
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Figure 2. Prolonged and tunable residence time of reversible covalent BTK inhibitors
(a) BTK inhibitors with methylpyrrolidine linkers characterized during residence time-based 
optimization. Compounds contain R (4-5, top) and S (6-9, bottom) linker configurations. 
Inhibitors 4, 7, 8, 9 contain a cyanoacrylamide electrophile, PP-ir contains an acrylamide 
electrophile, and PP-ne has no electrophile. (b) Dissociation curves of BTK inhibitors. 
Shown is the percent BTK with inhibitor bound (% BTK Bound) versus time (hrs) for a 108-
hour dissociation experiment. Residence times, τ, were determined as follows: 4: 22 ± 3 hrs; 
7: 34 ± 5 hrs; 8: 83 ± 14 hrs; 9: 167 ± 21 hrs; PP-ir: >200 hrs. Data from representative 
experiments are shown (mean ± SD, n = 2). (c) A 1-hour inhibitor dissociation study. 
Residence times, τ, were determined as follows: PP-ne: <0.1 hrs; dasatinib: 0.46 ± 0.6 hrs. 
Data from representative experiments are shown (mean ± SD, n = 2). (d) Prolonged 
residence time is tunable and not predicted by enzyme IC50 potency. A series of 21 
cyanoacrylamide-containing pyrazolopyrimidines with pyrrolidine linkers were 
characterized for both occupancy after 24 hrs in the biochemical off-rate assay (blue) and for 
potency in a BTK enzymatic activity assay (green). The occupancy at 24 hrs in the off-rate 
assay is plotted side-by-side with the IC50 for the same compound (mean ± SD, n ≥ 2). 
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Compounds were sorted left-to-right in descending order of durability, also see 
Supplementary Table 1.
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Figure 3. Long-term cellular durability of reversible covalent BTK inhibitors
(a) Sustained BTK occupancy of compound 9 in cells 4 hrs following inhibitor washout. 
Ramos B cells were incubated with various concentrations of 9 and either treated with 1 μM 
PP-BODIPY directly (top) or washed 3 times and returned to culture for 4 hrs prior to 
adding 1 μM PP-BODIPY (bottom). Lysates were evaluated both for binding of the PP-
BODIPY fluorescent probe to BTK (PP-BODIPY) and total BTK by Western blot (Total 
BTK) (n = 2). See Supplementary Fig. 25 for full gel images. (b) Reversible covalent BTK 
inhibitors exhibit distinct levels of durability in cells. Ramos B cells were incubated with 1 
μM inhibitor, washed 3 times, and returned to culture for 4 hrs prior to addition of 1 μM PP-
BODIPY. Lysates were evaluated both for binding of the PP-BODIPY probe and total BTK 
to calculate % Occupancy (mean ± SD, n ≥ 2) of the inhibitor (See Supplementary Fig. 14). 
(c) BTK occupancy of reversible covalent inhibitors 4 hrs and 18 hrs following cell washout 
(mean ± SD, n ≥ 2) evaluated using Alphascreen technology (Supplementary Fig. 15).
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Figure 4. Kinase selectivity of inhibitor 9
(a) Kinase selectivity of 9 evaluated at 1 μM and 0.1 μM in the Nanosyn 254 kinase panel. 
Circles indicate the 6 kinases that showed >90% inhibition at 1 μM. Large circles indicate 
the 2 kinases (BTK and BMX) that also demonstrated >90% inhibition at 0.1 μM. The figure 
was reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com). (b) 
Enzymatic IC50 curves determined using inhibitor 9 toward BTK and other kinases with a 
homologous cysteine with known tissue-specific homeostatic roles in vivo (EGFR, ERB-B2, 
ITK, JAK3) (mean ± SD, n ≥ 2). IC50 values and curves toward the other related cysteine-
containing kinases are shown in Supplementary Fig. 20. (c) Cellular selectivity of inhibitor 
9. The activity of 9 in Ramos B cells using a BTK occupancy assay (see Supplementary Fig. 
15) was compared with the activity toward ITK and EGFR in T cell receptor (TCR) and 
EGFR cellular reporter assays, respectively (mean ± SD, n ≥ 2). In the TCR assay, 9 was 
studied in a Jurkat T cell line stimulated with anti-CD3 plus anti-CD28 (to activate the T cell 
receptor pathway) and NFAT reporter expression was measured. In the EGFR assay, 9 was 
studied in ME-180 cervical carcinoma cells stimulated with EGF (to activate the EGFR 
receptor pathway) and AP-1 reporter expression was measured.
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Figure 5. Extended pharmacodynamic effect of an orally bioavailable BTK inhibitor
(a) PK/PD relationship for 9 in rats dosed orally at 40 mg/kg. The percent BTK occupancy 
(in blue) and the concentration of 9 in plasma (in green) at each time point following dosing 
is shown (mean ± SD, n = 3). The potency of 9 in the human whole blood CD69 expression 
assay was 146 ± 10 ng/ml. (b) The gel-based data used to calculate the BTK occupancy of 9. 
Occupancy was determined with in-gel fluorescence using rat PBMC collected from 3 
separate animals at each time point. The % BTK occupancy was determined from the 
percentage block of BODIPY probe compared to vehicle treated animals (ctrl) with all 
samples normalized for the total amount of BTK as evaluated by Western blotting (n = 2). 
See Supplementary Fig. 25 for full gel images.
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Figure 6. Inverted cyanoacrylamide FGFR inhibitors with prolonged, tunable residence time
(a) Model of the kinase ATP binding site demonstrating the disparate locations of cysteine 
residues targeted by cyanoacrylamide-based RSK2, BTK, and FGFR inhibitors. Structural 
elements are colored as follows: green:glycine rich loop; purple: αC-helix; cyan:DFG loop; 
yellow:hinge region; red: phosphate binding region. (b) Inverted cyanoacrylamides linked to 
a pyridopyrimidinone scaffold were synthesized with a variety of different capping groups. 
(c) Dissociation curves of FGFR inhibitors. Shown is the percent FGFR1 with inhibitor 
bound (% FGFR1 Bound) versus time (hrs) for a 24-hour dissociation experiment. 
Residence times, τ, were determined as follows: 28: >150 hrs; 29: 110 ± 41 hrs; 30: 18 ± 5 
hrs; BGJ398: 1.9 ± 0.4 hrs. Data from representative experiments are shown (mean ± SD, n 
= 2). (d) Prolonged and tunable residence time of inverted cyanoacrylamide FGFR 
inhibitors. FGFR inhibitors 28 through 38 containing a variety of electrophile capping 
groups were characterized (See compounds and durability data in Supplementary Table 4). 
Inhibitors were found to display a continuum of residence times as evaluated by the % 
FGFR1 occupancy 24 hours after addition of a fluorescent competitive tracer (orange bars) 
(mean ± SD, n ≥ 2). Residence time was not predicted by potency in a FGFR1 enzymatic 
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inhibition assay (purple bars) since IC50 potency for all compounds clustered in the range 
between 0.5 ± 0.05 nM and 6.0 ± 0.3 nM.
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